Drug profile · INN
penicillamine
D-PENAMINE
penicillamine (D-PENAMINE) is a copper chelating agent. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — penicillamine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 221
- Data quality
- 0.89
Quick answer
penicillamine (D-PENAMINE) is a copper chelating agent. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Copper chelating agent
Primary target: Copper
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12331328
CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome
granted -
US 12208167
Coated tablets for pH-dependent release of benzgalantamine
granted -
US 12201699
Compositions and methods for promoting homology directed repair
granted -
US 12188005
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
granted -
US 12156877
Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor
granted -
US 12036231
Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
granted -
US 11963982
CRISPR/RNA-guided nuclease systems and methods
granted -
US 11952408
HPV-specific binding molecules
granted -
US 11945822
Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase
granted -
US 11897932
Receptors for ligand-dependent transcriptional regulation
granted -
US 11801234
Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
granted -
US 11667911
Use of exonucleases to improve CRISPR/CAS-mediated genome editing
granted -
US 11666660
Glycan-dependent immunotherapeutic molecules
granted -
US 11597924
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
granted -
US 11566263
Compositions and methods for treating CEP290 associated disease
granted -
US 11512313
Functionally-interdependent shape switching nucleic acid nanoparticles
granted -
US 11453725
Methods for DNA-dependent targeting of a cell permeant antibody
granted -
US 11447563
Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
granted -
US 11400108
Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
granted
Frequently asked questions
What is penicillamine?
penicillamine (D-PENAMINE) is a copper chelating agent. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for penicillamine?
D-PENAMINE is a marketed brand name for penicillamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of penicillamine?
penicillamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.